NUZ Stock Overview
A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Neurizon Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.19 |
| 52 Week High | AU$0.54 |
| 52 Week Low | AU$0.082 |
| Beta | 1.6 |
| 11 Month Change | -9.52% |
| 3 Month Change | 2.70% |
| 1 Year Change | 120.93% |
| 33 Year Change | 104.30% |
| 5 Year Change | 90.00% |
| Change since IPO | -97.89% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About PharmAust's (ASX:PAA) Cash Burn Situation
Apr 09
Here's Why We're Not At All Concerned With PharmAust's (ASX:PAA) Cash Burn Situation
Mar 31Here's Why PharmAust Limited's (ASX:PAA) CEO Compensation Is The Least Of Shareholders Concerns
Nov 03Is PharmAust (ASX:PAA) In A Good Position To Deliver On Growth Plans?
May 30This Is The Reason Why We Think PharmAust Limited's (ASX:PAA) CEO Might Be Underpaid
Oct 14What Does PharmAust's (ASX:PAA) CEO Pay Reveal?
Feb 14Shareholder Returns
| NUZ | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 2.7% | -16.4% | 0.9% |
| 1Y | 120.9% | 32.3% | 18.4% |
Return vs Industry: NUZ exceeded the Australian Pharmaceuticals industry which returned 32.3% over the past year.
Return vs Market: NUZ exceeded the Australian Market which returned 18.4% over the past year.
Price Volatility
| NUZ volatility | |
|---|---|
| NUZ Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: NUZ has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: NUZ's weekly volatility has decreased from 14% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Michael Thurn | www.neurizon.com |
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease.
Neurizon Therapeutics Limited Fundamentals Summary
| NUZ fundamental statistics | |
|---|---|
| Market cap | AU$92.46m |
| Earnings (TTM) | -AU$8.90m |
| Revenue (TTM) | AU$841.71k |
109.8x
P/S Ratio-10.4x
P/E RatioIs NUZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NUZ income statement (TTM) | |
|---|---|
| Revenue | AU$841.71k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$841.71k |
| Other Expenses | AU$9.74m |
| Earnings | -AU$8.90m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,057.36% |
| Debt/Equity Ratio | 0% |
How did NUZ perform over the long term?
See historical performance and comparison